Company ProfilePremium

Cosmax Nbt, Inc.

Company Profile Analysis

Ticker: 222040.KQ코스맥스엔비티 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cosmax Nbt, Inc. - Company showcase

Year Founded & Workforce

2002

513 Employees

Cosmax Nbt, Inc. logo

Cosmax Nbt, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cosmax Nbt, Inc. Overview

Cosmax NBT is the health functional food contract-development and manufacturing arm of the Cosmax Group, the world's largest cosmetics ODM. It formulates and manufactures tablets, hard and soft capsules, powders, liquids, stick jellies and gummies for brand owners, retailers, pharmaceutical and food companies, direct-selling networks and online sellers in Korea, China, the US, Australia and Southeast Asia. Its production network spans Korea (Icheon), Australia (Melbourne, TGA-certified) and, until a 2025–26 restructuring, the US (Texas). The company differentiates on formulation technology: the micro-sized tablet platform a:dam, the chewable a:dam-MINI, the melt-in-mouth BoRrr format, micro-emulsion gummies and a dedicated probiotic line. It also develops proprietary individually recognized functional ingredients such as Respecta. After four years of net losses driven by overseas start-up costs, NBT reached record quarterly revenue and operating profit in 1H FY2026. More than 70% of its sales are export-linked, which makes it a leveraged play on China, cross-border e-commerce and "K-wellness" demand.


Company's own description

In its corporate materials, Cosmax NBT describes itself as a health functional food company whose businesses are: (i) research and development of functional raw materials and ingredients; (ii) manufacturing of health functional foods and health-oriented foods; and (iii) distribution of health functional foods (Google Finance company description, sourced from company filings). Its stated vision is to become the "2030 Global No.1 health functional food company." It describes a "one-stop service" covering product proposals tailored to local markets, regulatory support in each country, and design and marketing support for clients. That service is built on what the company calls Korea's largest health functional food plant in Icheon, Gyeonggi-do, plus a US–Australia–China supply chain (company recruiting profile on Saramin). The business-purpose clause lists manufacturing, sale, import/export and mail-order sale of health functional foods and processed health beverages (JobKorea).

Independent characterization

NBT is a mid-sized, capital-intensive contract manufacturer in a fragmented Korean HFF ODM market. It has an unusually high dependence on export and China-linked demand. Its economic model has three layers:

  1. ODM (Original Design Manufacturing). NBT develops the formulation and often the concept, then manufactures under the client's brand. This is the core revenue engine and earns higher gross margins than OEM because formulation IP and regulatory dossiers carry value.

  2. OEM. NBT manufactures to the client's specification. The company has said the US subsidiary historically relied on OEM work, a structural reason for that unit's losses.

  3. OBM (Original Brand Manufacturing). NBT supplies its own developed products and proprietary ingredients, which clients sell under their brands. Examples are individually recognized ingredients such as Respecta (women's vaginal-health probiotic) and the ashwagandha sleep ingredient, which carry pricing power and repeat-order characteristics.

Revenue model: Almost entirely product sales. In Q2 FY2026, products (manufactured goods) were 91% of revenue, merchandise (traded goods) 8% and other 1% (Butler.works, citing the 2Q26 filing). There is no subscription or licensing revenue of note. Ingredient know-how is monetized through product pricing rather than royalties.

Value-chain position: Midstream. NBT buys raw materials (vitamins, probiotics, botanical extracts, collagen, excipients and packaging), formulates, manufactures and packages finished dosage forms, and sells B2B. It does not own consumer brands at scale.

Customer types:

  • Korean brand owners and retailers. New 2026 channels named by Yuanta include convenience stores, Olive Young and Daiso.

  • Chinese brand owners selling through direct-selling (door-to-door) and cross-border e-commerce ("direct-purchase", 직구) channels.

  • US online and retail brands. The US subsidiary has been converted into a sales office supplied from Korea.

  • Australian and Southeast Asian clients served from the Melbourne plant, including the halal-certified route into Indonesia.

  • Pharmaceutical and food companies, and network-marketing companies.

End-markets: Korean HFF (estimated KRW 6.4 trillion in 2025), Chinese HFF and cross-border e-commerce, US dietary supplements, Australian complementary medicines, and emerging Indonesian (halal) and Indian demand.

Scale indicators: 32 countries and 300+ clients (Korea IR Council, 2022); "180+ clients" (company recruiting profile, undated). The company received the US$70 million Export Tower at the 62nd Trade Day in December 2025, seven years after its US$50 million tower in 2018 (Kukinews, 8 Dec 2025).

Strategy

Stated strategic themes

From company statements in press releases, award citations and the recruiting profile:

  1. "2030 Global No.1 health functional food company" (corporate vision).

  2. Research-centric ODM: differentiation through proprietary formulations (a:dam, a:dam-MINI, BoRrr, micro-emulsion) and individually recognized ingredients. The company describes itself as strengthening its position as an R&D-specialist company (Cosmorning, Nov 2025).

  3. Global supply chain with country-specific competence: Korea, the US, Australia and China, with organic collaboration between hubs (Cosmorning, Nov 2025).

  4. Digital transformation and systematization: company-wide management systems and big-data prescription automation, cited in the Presidential Commendation (Nov 2025).

  5. "Snackification": described by Cosmax Group as a core trend reshaping global HFF; capacity investment in jelly, gummy and liquid-stick formats (Dailian, Jun 2026).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionStatus
US manufacturing exit2025–2026First Texas plant sold (US$14.25M); second sale planned for 2026; US entity converted to a sales office supplied from KoreaFirst sale completed; second pending (a subsidiary asset-disposal decision was filed 28 Jul 2026)
Australia recapitalizationSep 2024; Jul 2026KRW 3.6bn and KRW 10.4bn share subscriptions to restore equity and "secure production capability"Completed; 100% owned
Cosmax NS absorptionMar–Jun 2026KRW 3.8bn buy-in of remaining shares, then a small-scale, no-new-share merger (ratio 1:0)Completed 30 Jun 2026; registration 3 Jul 2026
Snack-format capacity1H 2026Stick-jelly line upgraded from 5-row to 12-row filler; monthly capacity roughly doubled from 15M sachets; gummy forming/filling equipment addedCompleted
New domestic channels2,026Supply to convenience stores, Olive Young and Daiso private-label / brand partnersContributing (Yuanta, Sep 2026)
Halal / Indonesia2024 onwardMUI halal certification via the Australian plant; inner-beauty HFF with Cosmax Indonesia—
India2024 onwardAshwagandha-based collaboration; OBM functional coffeePipeline
Trade showsJun 2026HNC 2026 (Shanghai, 15–17 Jun) with Cosmax Bio: snack formats, a:dam, PDRNCompleted
K-beauty crossover2,026Yuanta flags potential ODM/OEM collaboration with K-beauty companies on inner-beauty productsProspective
Tax recovery2Q 2026KRW 25.7bn corporate-tax refund from a correction claimRecognized in 2Q26

Medium-term financial targets

MetricFY2025FY2026FFY2027F
Operating income (KRW bn)4.035.942.3
Net income (KRW bn)-15.021.026.0

Management has not publicly disclosed numeric medium-term targets or formal guidance in the sources reviewed. The quantitative framework below comes from sell-side forecasts.

Sources: DS Investment & Securities. Operating income forecasts are from 10 Aug 2026; net income forecasts are from 8 May 2026 (before the 2Q26 tax refund, which will raise the FY2026 figure). DS's implied FY2026 revenue is about KRW 399bn (1H actual KRW 195.5bn plus 2H forecast KRW 203.5bn).

ESG and sustainability commitments

No company-specific emissions targets or sustainability-linked financing were identified.

Products & Services

Prices are not publicly disclosed; B2B pricing is negotiated per project. Launch years are given where verifiable.

Dosage-form platforms (manufacturing capabilities)

PlatformDescription / capabilityTarget customersYear / statusSource
Tablets (conventional)Compressed tablets, coated and uncoatedBrand owners, pharma, network marketingLegacy coreKorea IR Council, 2022
Hard capsulesPowder-fill hard capsulesBrand ownersLegacy coreHi Investment, 2021
Soft capsulesOil-based actives (e.g., krill oil, omega-3)Brand owners; online / home-shopping channelsLegacy coreeBest, Aug 2020 (krill oil demand)
Powders / sticksPowder sachets and sticks; a historical strengthProbiotic and collagen brandsLegacy coreKorea IR Council, 2022
LiquidsDrinkable ampoules and liquid shots; another historical strengthBeauty-from-within and energy brandsLegacy coreKorea IR Council, 2022
Stick jelly (back-seal sticks)Jelly/gel sachets; 12-row filling line added in 1H26 alongside the older 5-row line, roughly doubling monthly capacity from 15M sachets"Snackification" brands; export clientsUpgraded 2026Dailian; Cosinkorea, Jun 2026
GummiesMolded gummies with new forming and filling equipment; micro-emulsion technology improves stability of fat-soluble activesConvenience-store, Olive Young and Daiso channels; exportExpanded 2026Cosinkorea, Jun 2026; Yuanta, Sep 2026
Dedicated probiotic line (EPP)Described as the industry's first dedicated probiotic production lineProbiotic brandsOperatingCompany profile (Saramin)
MultipacksMulti-supplement daily packs; sales up about 85% in 2023Personalized-nutrition and subscription brandsGrowingCosmorning

Proprietary formulation technologies

TechnologySpecificationTarget useYearSource
a:dam™ (아담)Micro-sized tablet; proprietary process cuts non-functional excipient by up to 87% and tablet size by up to 66% while keeping active content and stabilityMultipacks, older consumers, pill-fatigue segmentsShown HNC 2024; AAES award 2024Cosmorning
a:dam™-MINICrunchy micro-tablet chewed without water; about 0.35 cm per pieceChildren, seniorsLaunched 2024Cosmorning
BoRrr (보르르)Fast-melting format that dissolves easily in the mouthConvenience-focused consumersCited 2025Cosmorning, Nov 2025
Micro-emulsionEmulsification technology for gummies and jellies with improved bioavailability and stabilityGummy/jelly ODMCited 2026Yuanta, Sep 2026; company profile
Digital prescription automationBig-data-based formulation/prescription automation systemInternal R&D productivityCited Dec 2025Kukinews, Dec 2025

Proprietary ingredients and branded actives (OBM)

Ingredient / productFunctionStatusSource
Respecta (리스펙타)Women's vaginal-health probiotic (individually recognized functional ingredient)Sales about KRW 6bn in 1Q21, roughly double the 2020 quarterly averageIBK, May 2021
Collagen productsSkin health; distribution expanded in 2021OngoingIBK, May 2021
Ashwagandha (sleep)Individually recognized by Korea's MFDS for sleep function; basis for India collaborationApproved; India OBM plannedDealsite, Mar 2024
Joint-health ingredientIndividually recognized ingredientLaunched 2Q22IBK, Apr 2022
Skin-health ingredientIndividually recognized ingredientLaunched 2021IBK, May 2021
Functional coffee (OBM)Planned product for IndiaPipelineDealsite, Mar 2024
PDRN materialShown with Cosmax Bio at HNC 2026Commercialization stage not disclosedCosinkorea, Jun 2026
Inner-beauty HFF for IndonesiaSkin improvement and body-fat reduction, developed with Cosmax Indonesia's halal know-howPlannedDealsite, Mar 2024

Services

Regulatory affairs: country-specific registration support (Korea MFDS, Australia TGA, US NSF-certified manufacturing, Indonesia MUI halal).

Design and marketing support: packaging design and launch support for clients.

Certifications held: NSF, TGA, K-GMP, ISO 22000, HALAL, HACCP (company profile, Saramin).

Financial Narrative

All figures: K-IFRS consolidated, KRW millions, fiscal years ending 31 December. Source: S&P Global Market Intelligence via StockAnalysis.com, unless stated otherwise.

Income statement

Cross-check: Butler.works (FnGuide-type data) reports operating income of KRW 6.4bn / 2.2bn / 12.0bn / 9.9bn / 4.0bn and net income of KRW -5.3bn / -12.9bn / -5.8bn / -5.4bn / -15.1bn for FY2021–FY2025. The small net-income gaps reflect consolidated versus controlling-interest presentation.

Margins and growth

Revenue CAGR FY2021–FY2025: -0.2% a year (analyst calculation: 287,479 / 289,347 over four years).

Quarterly bridge (FY2025 → 1H FY2026)

Sources: Kormedi (2Q26 and 1H26/1H25 preliminary figures); Herald Economy (1Q26); Google Finance (3Q25 and 4Q25 revenue); DS Investment (quarterly OI). 1Q25 revenue and net income are derived by subtracting 2Q25 from the 1H25 totals (1H25 revenue KRW 147.83bn, OI KRW 3.39bn, net loss KRW 3.42bn). The 2Q26 net income includes a KRW 25.7bn corporate-tax refund from a correction claim (경정청구) (DS Investment, 10 Aug 2026).

1H FY2026 vs 1H FY2025: revenue KRW 195.53bn vs 147.83bn (+32.3%); operating income KRW 18.75bn vs 3.39bn (+452.8%); net income KRW 39.46bn vs -3.42bn.

Balance sheet

Interim position, 30 June 2026 (S&P): total assets KRW 334.6bn; cash KRW 52.7bn; short-term borrowings KRW 156.7bn; current LT debt KRW 2.5bn; long-term debt nil; total debt KRW 161.3bn; net debt KRW 108.6bn; equity KRW 92.4bn (minority interest removed after the subsidiary mergers and buy-ins); working capital KRW -40.1bn; book value per share KRW 4,494.

The FY2024 increase in equity from KRW 40.6bn to KRW 62.0bn came mainly from other comprehensive income, which rose from KRW 2.3bn to KRW 29.4bn.

Cash flow

The FY2025 "other investing" inflow of KRW 20.6bn matches the US$14.25M first US plant sale (about KRW 20bn at prevailing exchange rates). The company said these proceeds would go toward debt repayment (Herald Economy, May 2026). Trailing twelve months to June 2026: OCF KRW 31.0bn, capex KRW 12.6bn, FCF KRW 18.4bn, net debt repaid KRW 40.9bn (S&P).

Ratios (analyst calculations from the S&P data above)

At 30 June 2026, debt/equity had improved to 1.75x and the current ratio to 0.82x. S&P reports TTM interest coverage of 1.42x (at end-March 2026), an Altman Z-score of 0.96 and a Piotroski F-score of 5.

Commentary: trends, inflections and drivers

Revenue (FY2021–FY2025). Revenue peaked at KRW 333.6bn in FY2023, then fell two years running to KRW 287.5bn in FY2025, below the FY2021 level. The FY2025 shortfall was severe against expectations: in February 2025, DS Investment had forecast FY2025 revenue of KRW 350.8bn (+10%) and operating profit of KRW 20.9bn. Actual results were 18% and 81% lower. The drivers named by brokers and the company were:

  • a high base from a major client's new-product launches in 2024;

  • order gaps at existing customers;

  • the halt of US production as plants were sold, which removed US manufacturing revenue (Herald Economy, May 2026);

  • provisioning and one-off disposal costs.

Gross margin. Gross margin held in a narrow 11.6–14.5% band. It reflects heavy fixed costs: PP&E of more than KRW 100bn against sales of about KRW 300bn, and under-utilized overseas plants. The FY2022 trough (11.6%) coincided with the US two-plant structure running below capacity. The jump to 20.0% in 1Q26 (COGS KRW 74.6bn on revenue KRW 93.3bn, per Google Finance) shows the operating leverage once US fixed costs were removed and Korean volumes rose.

Operating to net income. Net losses occurred in every year despite positive operating profit. Two items explain the gap: (i) interest expense of KRW 10–12bn a year since FY2023, on short-term borrowings rolled at higher Korean rates; and (ii) tax expense structurally above pre-tax income. Profitable Korean operations paid tax while overseas losses produced no deferred-tax benefit, so effective rates exceeded 1,000% in FY2023–FY2024. FY2025 also included KRW 3.8bn of asset-disposal losses and KRW 4.0bn of write-downs.

Balance sheet. Funding is almost entirely short-term. Short-term borrowings of KRW 156.7bn are about 97% of total debt at 30 June 2026, so the company depends on annual bank rollovers. Working capital was negative throughout, and S&P's current ratio of 0.68 (TTM) and Z-score below 1 flag elevated financial risk on paper. Deleveraging since FY2024 is real: total debt fell from KRW 203.9bn (FY2023) to KRW 161.3bn (Jun 2026), helped by the US asset sale, positive FCF and the 2Q26 tax refund. The second US plant sale (proceeds again earmarked for debt reduction) and 2H26 earnings are the next steps.

Cash generation. FCF turned consistently positive from FY2024 (KRW 4.8bn) to FY2025 (KRW 9.4bn) and TTM June 2026 (KRW 18.4bn). Capex has stayed modest (KRW 4–18bn), concentrated on Korean formulation lines (stick jelly, gummies) rather than new plants.

Inflection. 1H FY2026 marks a clear break. Quarterly operating margins of 8–11% compare with a 0.7–3.6% annual range in FY2021–FY2025. If 2H26 delivers the KRW 17.1bn operating profit DS forecasts, FY2026 operating income of about KRW 36bn would be roughly three times the previous record (FY2023: KRW 12.0bn).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryFunctionStatus (Oct 2026)

Cosmax NBT, Inc. (parent, "Korea standalone")

Korea

HQ, R&D, Icheon manufacturing, export hub

Core profit center

Cosmax NS (formerly Nutri Science)

Korea

Functional ingredient / materials subsidiary

Absorbed into parent, 30 Jun 2026

Cosmax NBT USA

US (Dallas, Texas)

Formerly manufacturing; now a sales-centric entity supplied from Korea

First plant sold 2025; second sale planned for 2026

Cosmax NBT Australia Pty Ltd

Australia (Melbourne)

TGA-certified manufacturing; China, Australia and halal/SEA exports

100% owned; recapitalized 2024 and 2026

Cosmax NBT Shanghai

China

Sales subsidiary

Operating (scale not separately disclosed recently)

Group Entities (FY2021)

Entity (share of pre-elimination revenue, %)FY2021

Korea standalone (%)

62.2

US subsidiary (%)

11.4

Australia subsidiary (%)

10.0

Shanghai subsidiary (%)

10.7

Cosmax NS (%)

5.7

Revenue by Segment

MetricFY2024FY2025

US subsidiary revenue (KRW Bn)

21.722.0

US subsidiary operating income (KRW Bn)

-17.0-7.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (FY2022–FY2023)

MetricFY2022FY2023

Australia subsidiary revenue (KRW Bn)

57.074.7

Revenue by Segment (FY2025)

MetricFY2025

Korea standalone revenue (KRW Bn)

206.9

Segment Revenue

Metric1Q252Q253Q254Q251Q262Q26

US subsidiary revenue (KRW Bn)

5.68.54.03.93.54.9

US subsidiary operating income (KRW Bn)

-3.6-1.0-2.0-1.2-0.2—

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

289,347328,207333,631317,985287,479

Revenue growth (%)

8.4613.431.65-4.69-9.59

Cost of revenue (KRW Mn)

251,619290,235285,300273,954246,817

Gross profit (KRW Mn)

37,72837,97348,33044,03140,662

SG&A (KRW Mn)

27,39332,90133,72329,87732,891

Operating income (KRW Mn)

6,4342,24011,9779,9054,003

D&A (KRW Mn)

15,58115,81413,54314,16112,485

EBITDA (KRW Mn)

22,01518,05425,52024,06616,488

Interest expense (KRW Mn)

5,2827,81711,70111,57510,013

Pre-tax income (KRW Mn)

2,308-4,543409405-13,822

Income tax expense (KRW Mn)

7,6498,3726,2385,8531,257

Net income attributable to owners (KRW Mn)

-6,393-13,070-6,493-5,754-15,037

EPS basic (KRW)

-309.93-633.61-314.76-279.00-731.57

EPS diluted (KRW)

-309.93-633.61-314.76-279.00-731.57

Dividends per share (KRW)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

13.0411.5714.4913.8514.14

Operating margin (%)

2.220.683.593.121.39

EBITDA margin (%)

7.615.507.657.575.73

Net margin (%)

-2.21-3.98-1.95-1.81-5.23

Financial Analysis

Metric1Q252Q253Q254Q251Q262Q26

Revenue (KRW Bn)

72.275.765.774.093.3102.3

Operating income (KRW Bn)

0.92.5-1.21.810.38.5

Operating margin (%)

1.23.3-1.82.411.08.3

Net income (KRW Bn)

-2.3-1.1——9.130.3

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Mn)

310,464303,971300,078317,246282,959

Cash & equivalents (KRW Mn)

56,48263,88559,52945,26748,322

Accounts receivable (KRW Mn)

42,87942,89748,25048,07041,209

Inventory (KRW Mn)

49,53242,86635,45937,67039,433

Total current assets (KRW Mn)

156,616159,271151,659144,400136,164

PP&E (KRW Mn)

146,717108,329112,368133,328104,109

Goodwill & intangibles (KRW Mn)

1,3009047781,047764

Short-term borrowings (KRW Mn)

129,806144,137150,054170,199159,156

Current portion of LT debt (KRW Mn)

25,91824,97536,00018,5334,167

Long-term debt (KRW Mn)

45,91236,50013,3941,6671,250

Lease liabilities, total (KRW Mn)

2,1842,1914,4443,2692,912

Total debt incl. leases (KRW Mn)

203,819207,803203,892193,668167,484

Net debt (KRW Mn)

147,336143,918144,362148,401119,162

Total current liabilities (KRW Mn)

198,120212,093233,628237,166214,951

Total liabilities (KRW Mn)

252,048256,717259,487255,244234,117

Equity attributable to owners (KRW Mn)

55,35843,51336,20557,34344,228

Total equity (KRW Mn)

58,41647,25440,59162,00248,842

Working capital (KRW Mn)

-41,505-52,822-81,969-92,766-78,787

Book value per share (KRW)

2,683.612,109.421,761.402,789.762,151.69

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Mn)

-8,19013,61216,7809,11418,263

Capital expenditure (KRW Mn)

-4,746-6,006-17,383-4,317-8,843

Free cash flow (KRW Mn)

-12,9367,606-6034,7979,421

Proceeds from PP&E sales (KRW Mn)

1,8623,6353,67047690

Other investing inflows (KRW Mn)

6089165462820,607

Dividends paid (KRW Mn)

00000

Share buybacks (KRW Mn)

0052200

Net debt issued / repaid (KRW Mn)

394-5,439-7,665-19,887-28,850

Cash interest paid (KRW Mn)

5,2837,35413,73911,68410,371

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE on year-end owners' equity (%)

-11.55-30.04-17.93-10.03-34.00

ROA on year-end assets (%)

-2.06-4.30-2.16-1.81-5.31

Pre-tax ROIC, EBIT / (net debt + equity) (%)

3.131.176.484.712.38

Current ratio (x)

0.790.750.650.610.63

Debt / equity (x)

3.494.405.023.123.43

Net debt / EBITDA (x)

6.697.975.666.177.23

Interest coverage, EBIT / interest (x)

1.220.291.020.860.40

Asset turnover (x)

0.931.081.111.001.02

Days sales outstanding (days)

54.147.752.855.252.3

Days inventory outstanding (days)

71.953.945.450.258.3

Days payables outstanding (days)

36.626.334.338.041.8

Cash conversion cycle (days)

89.475.363.967.468.8

Revenue by Region (%) and Revenue by Region

MetricFY2022FY2024FY2025

Overseas share of revenue (%)

627070

Domestic share of revenue (%)

383030

Implied overseas revenue (KRW Bn)

203.5222.6201.2

Implied domestic revenue (KRW Bn)

124.795.486.2

Share Price History

DatePrice (KRW)Source

4 Aug 2020

9,390

Hana Financial Investment

7 Jun 2021

11,450

Kiwoom Securities

24 Feb 2025

3,360

DS Investment

7 May 2026

5,230

DS Investment

24 Jul 2026

7,470

StockAnalysis

7 Aug 2026

8,630

DS Investment; Kormedi

10 Aug 2026

10,700

StockAnalysis (+23.99% on the day)

21 Aug 2026

8,060

StockAnalysis

15 Sep 2026

7,380

Google Finance

Latest snapshot (undated, Sep–Oct 2026)

8,310

Butler.works

Valuation Multiples

MultipleCosmax NBTBasis / source

Market cap (KRW Bn)

171.4

Butler.works at KRW 8,310

Enterprise value (KRW Bn)

About 280

Market cap plus Jun-26 net debt of KRW 108.6bn (analyst)

P/E (TTM)

6.15

Butler.works; TTM net income KRW 27.9bn includes the KRW 25.7bn tax refund

P/E (forward)

4.64

Butler.works

EV/EBITDA (TTM Jun-26)

About 9.3

EV KRW 280bn / TTM EBITDA about KRW 30.1bn (analyst)

EV/Sales (TTM Jun-26)

About 0.84

EV / TTM revenue KRW 335.2bn (analyst)

P/B

1.85

Butler.works; equity KRW 92.4bn

Beta (5Y)

0.92

S&P

Analyst Ratings & Targets

BrokerDateRatingTarget price (KRW)

DS Investment & Securities

25 Feb 2025

Buy

6,000

DS Investment & Securities

8 May 2026

Buy

10,000

DS Investment & Securities

10 Aug 2026

Buy

12,000

Hana Securities

8 Jul 2026

Not rated (preview)

—

Yuanta Securities Korea

7 Sep 2026

No rating

—

Consensus (3 brokers)

Latest

—12,000

Analyst Conclusions

Guidance and consensus

Management guidance: none published in quantitative form. Qualitatively, management highlights new domestic channels, export growth to China, the US and Southeast Asia, snack-format capacity and formulation technology.

Sell-side (DS, Aug 2026): - 2H26 revenue KRW 203.5bn (+46% YoY) and OI KRW 17.1bn.

  • FY2026 OI KRW 35.9bn; implied FY2026 revenue about KRW 399bn (+39%).

  • FY2027 OI KRW 42.3bn (+18%).

Next catalyst: 3Q26 preliminary results, expected in early-to-mid November 2026 (the 3Q25 results were filed 7 Nov 2025). DS's 3Q26 OI forecast was KRW 9.0bn (May 2026 version: KRW 7.9bn).

Bull case

  1. Structural margin reset: removing US manufacturing fixed costs plus Korean operating leverage lifted gross margin to 17.6–20.0% in 1H26 (vs 14.1% in FY2025). A sustained 8–10% operating margin on about KRW 400bn of revenue supports the KRW 36–42bn OI trajectory.

  2. Deleveraging flywheel: the US plant proceeds (US$14.25M already, more pending), the KRW 25.7bn tax refund and TTM FCF of KRW 18.4bn have already cut debt/equity from 3.43x to 1.75x in six months. Each KRW 10bn of debt repaid saves roughly KRW 0.5–0.6bn of interest a year (analyst estimate at prevailing rates).

  3. Channel diversification: new retail channels (convenience stores, Olive Young, Daiso) and K-beauty inner-beauty crossover reduce reliance on China direct-selling, while snack-format capacity has doubled.

Bear case

  1. Earnings quality and credibility: 2Q26 net income of KRW 30.3bn is about 85% one-off (the tax refund). The FY2025 miss against forecasts (OI KRW 4.0bn vs KRW 20.9bn expected) shows how quickly a concentrated client base can erode earnings.

  2. China dependence: the company remains among the most China-exposed Korean consumer stocks. A repeat of the 2022 direct-selling slump would hit both the Korean and Australian plants.

  3. Balance-sheet fragility persists: about 99% of debt is due within 12 months, the current ratio is 0.82x, and S&P's Altman Z-score is 0.96. A credit squeeze or a weak quarter could force further affiliate support, and minority shareholders are already litigating governance issues.

Catalysts and monitorables (next 12 months)

  • 3Q26 and 4Q26 results: whether operating margin holds above 8% without one-offs.

  • Completion and pricing of the second US plant sale (the 28 Jul 2026 asset-disposal filing).

  • Australian subsidiary profitability after the KRW 10.4bn July 2026 recapitalization.

  • FY2026 Annual Business Report (around March 2027): net debt, refinancing terms, any dividend-policy statement.

  • Progress of minority-shareholder litigation and any change in auditor or board composition.

  • Halal (MUI) certification and first Indonesian or Indian commercial orders.

  • Cosmax BTI governance after the September 2026 leadership change.

  • KRW/USD and KRW/CNY moves, and US tariff policy on Korean-made supplements.

Analyst verdict

Cosmax NBT is a classic restructuring-to-recovery story that has moved from thesis to evidence in 2026. For most of the past decade the company was a reasonable Korean HFF manufacturer weighed down by an overseas footprint it could not fill. Texas and Melbourne plants built ahead of demand produced years of losses, negative subsidiary equity, KRW 10–12bn of annual interest expense and five straight years of net losses. Management's response has been decisive: consolidate and then sell the US plants, turn the US into a sales office supplied from Korea, recapitalize Australia, absorb Cosmax NS, and concentrate investment on high-velocity Korean formulation lines. The results are visible. Quarterly operating margins of 8–11% in 1H26 compare with a five-year annual peak of 3.6%, and debt/equity has halved in six months.

The investment debate now turns on durability, not direction. Normalized earnings are smaller than headline TTM P/E suggests because the 2Q26 tax refund flatters net income, and growth still depends heavily on China-linked and newly won domestic retail clients whose order patterns have proven volatile. The capital structure, nearly all short-term bank debt, leaves little room for a stumble, and governance friction with minority investors is an overhang that the controlling group has not resolved transparently.

On balance, at about KRW 8,300 (EV about KRW 280bn, about 9x TTM EV/EBITDA and about 7–8x DS's FY2026 OI), the market has priced in a good share of the turnaround. The KRW 12,000 consensus target implies further upside only if 2H26 confirms DS's KRW 17bn operating profit forecast without one-offs. We would characterize the shares as a high-beta, catalyst-driven recovery position. The upside requires continued quarterly execution and visible deleveraging. Investors should size positions with the company's financial fragility and forecasting history in mind, and treat the 3Q26 print as the key test.


End of dossier. All figures are in KRW unless otherwise stated.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior roles / notes

Kim Nam-joong (김남중)

CEO / Representative Director

Since Mar 2025

Cosmax production head (EVP-level, promoted Jan 2021); promoted to vice-president and named NBT CEO-designate Dec 2024; Minister of Trade, Industry and Energy commendation, Dec 2025

Park Jong-cheol (박종철)

Head of Production; promoted to Managing Director (상무)

Promoted Dec 2024

Production division

Kim Ui-taek (김의택)

Managing Director (상무)

Promoted effective 1 Jan 2026

—

Lee Su-yeon (이수연)

Junior Managing Director (상무보)

Appointed effective 1 Jan 2026

—

Major Shareholders

HolderStakeSource / date

Cosmax BTI, Inc. (direct)

43.53–43.68%

Herald Economy, May 2026; Cosmax BTI disclosures (etfshopping)

Cosmax BTI plus 11 related parties

44.0% (Aug 2026); 44.5% (May 2026)

DS Investment

Treasury stock (incl. related)

0.4%

DS Investment

Foreign investors

5.3% (Aug 2026), up from 1.25% (May 2026)

DS Investment

Insiders (per S&P definition)

0.45%

S&P / StockAnalysis

Free float

About 11.48M shares (~56%)

S&P / StockAnalysis

Competitive Landscape

Key Competitors

CompetitorListingPositioningFY2025 revenue (KRW Bn)FY2025 OI (KRW Bn)NotesSource

Kolmar BNH

KOSDAQ: 200130

Largest Korean HFF ODM by revenue; Atomy-linked; Haleon partnership

574.926.6

FY2025 net loss KRW 22.6bn; Chinese subsidiary in negative equity

Butler.works; Dealsite

Novarex

KOSDAQ: 194700

No.1 Korean HFF ODM by capacity; 49 individually recognized ingredients

404.3

43.1 (10.65% OPM)

ROE about 15%; FY26E P/E about 6.2x

AlphaDistill

Seoheung

KOSPI: 008490

No.1 Korean hard-capsule maker; HFF OEM

——

Trailing P/E about 5.2x

AlphaDistill

Cosmax Bio

Unlisted (Cosmax BTI subsidiary)

Sister HFF ODM; stick jelly, liquid sticks

——

Exports US$5.41M (Jul 2024–Jun 2025)

Kukinews

Chong Kun Dang Bio

KOSDAQ

Probiotic ingredients (supplier to the "Lactofit" brand)

——

Ingredient competitor

Hankyung Business, 2020

Nutri (뉴트리)

KOSDAQ

Brand / ODM

——

Loss-making or break-even in 2025

AlphaDistill

HL Science

KOSDAQ

Ingredients / brand

——

Loss-making or break-even in 2025

AlphaDistill

Frombio

KOSDAQ

Ingredients / ODM

——

Loss-making or break-even in 2025

AlphaDistill

Natural Way

Private

HFF OEM/ODM

——

Named peer

TheVC

Kwangdong Health Bio

Private

HFF OEM/ODM

——

Named peer

TheVC

Huons N

Private / affiliate

HFF

——

Named peer

TheVC

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricCosmax NBTKolmar BNHNovarex

Revenue (KRW Bn)

287.5574.9404.3

Revenue growth (%)

-9.6-6.6—

Operating margin (%)

1.44.610.65

Net income (KRW Bn)

-15.0-22.6—

Company Snapshot

$202.3M

Revenue

513

Employees

2002

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Earnings inflection proven in two consecutive quarters: 1Q26 OI KRW 10.3bn and 2Q26 OI KRW 8.5bn versus FY2025 full-year OI of KRW 4.0bn (company preliminary disclosures).
  • Formulation IP with external validation: AAES Technology Breakthrough Award for a:dam (2024); Presidential Commendation for productivity (Nov 2025).
  • Export franchise: US$70M Export Tower (Dec 2025); overseas share above 70% (2025).
  • Certifications across four regulatory regimes: NSF, TGA, HALAL, K-GMP and others (company profile).
  • Positive and rising FCF: KRW 4.8bn (FY2024) → KRW 9.4bn (FY2025) → KRW 18.4bn (TTM Jun 2026) (S&P).
  • Group backing: Cosmax BTI has repeatedly funded subsidiaries, and the group is co-locating HFF R&D in Pangyo (Dealsite, Jan 2026).

Weaknesses

  • Five consecutive years of net losses, FY2021–FY2025 (cumulative about KRW -46.7bn attributable) (S&P).
  • Short-term funding concentration: short-term borrowings of KRW 156.7bn are about 97% of total debt (Jun 2026) (S&P).
  • Thin interest coverage: EBIT/interest of 0.40x in FY2025 and below 1.3x in every year FY2021–FY2025 (analyst calculation).
  • History of failed overseas manufacturing: US losses of KRW 17.0bn (FY2024) and KRW 7.8bn (FY2025); US entity in negative equity since end-2022.
  • Low structural margins: operating margin never above 3.6% in FY2021–FY2025.
  • Forecasting credibility: FY2025 OI of KRW 4.0bn against a February 2025 broker forecast of KRW 20.9bn.

Opportunities

  • K-beauty → K-inner-beauty cross-sell via Cosmax's global client base (Yuanta flags potential ODM collaboration with K-beauty firms).
  • New domestic retail channels (convenience stores, Olive Young, Daiso), already contributing in 2026.
  • Snack-format capacity doubling, positioned for global "snackification" demand (Jun 2026).
  • Halal Indonesia and India via MUI certification and the ashwagandha ingredient (2024 strategy).
  • Deleveraging catalysts: the second US plant sale and the KRW 25.7bn tax refund cut interest drag.
  • Multipack / personalized nutrition: multipack sales up about 85% in 2023; a:dam is designed for this segment.

Threats

  • China demand volatility: the 2022 slump, and NBT's status as the most China-exposed Korean food stock (DS, Feb 2025).
  • Peer competition: Novarex earns more than 10% margins with greater capacity; Kolmar BNH has more than twice NBT's revenue.
  • FX risk: with more than 70% of revenue export-linked, KRW appreciation would compress margins. 1Q21 margin compression was attributed partly to translation effects (IBK).
  • Client concentration: the FY2025 decline was linked to a major client's high base and order gaps (DS, Feb 2025).
  • Refinancing risk if Korean bank credit tightens, given the reliance on rolling short-term lines.
  • Governance friction: minority-shareholder litigation and the parent's leadership change (Heo Min-ho resignation, Sep 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 Apr 2025Money Today reports Korean HFF manufacturers expect revenue and profit growth in 2025; NBT shares +9.97% that day (KRW 7,280 quoted in a later page refresh)Sector sentiment
13 May 20251Q25 preliminary results filedWeak start: 1Q25 OI about KRW 0.9bn
13 Aug 20252Q25 preliminary results: revenue KRW 75.65bn, OI KRW 2.52bn, net loss KRW 1.13bnBelow 2025 forecasts
–First US plant sold for US$14.25MExit from US manufacturing
7 Nov 20253Q25 preliminary results: revenue KRW 65.7bn, operating loss KRW 1.2bn; one-off disposal expense at the US subsidiaryTrough quarter
5 Nov 2025Presidential Commendation, 49th National Productivity AwardsRecognition of digital and process innovation
8 Dec 2025US$70M Export Tower; CEO receives Minister of Trade, Industry and Energy commendationExport scale milestone
29 Dec 2025Cosmax Group 2026 executive reshuffle: Kim Ui-taek (MD) and Lee Su-yeon (junior MD) promoted at NBTManagement bench
Feb 2026FY2025 results: revenue KRW 287.5bn (-9.6%), OI KRW 4.0bn (-59.6%), net loss KRW 15.1bnWorst bottom line of the five-year window
4 Mar 2026DS Investment sector note names NBT a "stock of interest" at about 7x FY2026 P/E; expects business-restructuring-led turnaroundSell-side re-engagement
17 Mar 2026Additional Cosmax NS shares acquired for KRW 3.8bnPre-merger consolidation
Apr 2026Board decides absorption merger of Cosmax NS (small-scale, no new shares)Structural simplification
7 May 20261Q26 preliminary: revenue KRW 93.3bn (+29.2%), OI KRW 10.3bn (+1,080%), net income KRW 9.1bn (turnaround) — company record on both revenue and OIEarnings inflection
8 May 2026Shares limit-up after hours; Cosmax BTI rallies more than 20% intraday; DS raises target price to KRW 10,000Re-rating begins
15 Jun 2026Cosmax Group announces more than doubled snack-format HFF capacity (NBT stick jelly roughly x2)Capacity for exports
15–17 Jun 2026HNC 2026 exhibition, ShanghaiChina client acquisition
30 Jun 2026Cosmax NS merger completedStructure simplified
8 Jul 2026Hana Securities preview expects 2Q26 OP about +245%Positive preview
15 Jul 2026KRW 10.4bn additional investment in the Australian subsidiary; subsidiary rights-offering decision filedRecapitalization
28 Jul 2026Subsidiary tangible asset disposal decision filed–
7 Aug 20262Q26 preliminary: revenue KRW 102.26bn (+35.2%), OI KRW 8.47bn (+236.2%), net income KRW 30.31bnFirst quarter above KRW 100bn
10 Aug 2026DS raises target price to KRW 12,000; stock closes +24% at KRW 10,700; market cap passes KRW 200bn intraday (MTN)Peak re-rating
13 Aug 2026Half-year report (2026.06) filedPeriodic disclosure
7 Sep 2026Yuanta initiates commentary (no rating or target price): formulation competitiveness is a differentiatorBroader coverage
10 Sep 2026Heo Min-ho resigns as Cosmax BTI co-CEO; Lee Byung-joo becomes sole CEO of the parentParent governance change
15 Sep 2026Shares at about KRW 7,380 (Google Finance), well below the KRW 11,200 52-week highPost-spike consolidation
21 Sep 2026Cosmax Group 2H26 graduate recruitment includes NBT (R&I, sales, QA/QC)Hiring for growth
Sep–Oct 2026Active job postings for domestic sales, strategic marketing, regulatory affairs, R&D and Icheon productionCapacity and commercial build-out

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue fell from KRW 289.3 Bn in FY2021 to KRW 287.5 Bn in FY2025.
Cosmax Nbt, Inc. — Income Statement: Revenue & Gross Profit
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Revenue289.3328.2333.6318287.5
Cost of revenue251.6290.2285.3274246.8
Gross profit37.73848.34440.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.